A Meta-analysis Of The Efficacy And Safety Of Tamsulosin In Combination With Finasteride In Patients With BPH

Objective:Through evidence-based medicine,a systematic evaluation of the clinical efficacy and safety of combination therapy with tamsulosin and finasteride versus monotherapy with tamsulosin in patients with Benign Prostatic Hyperplasia(BPH)was conducted.This provides the best treatment strategy for clinical practice,improving patient symptoms and quality of life.Methods:By searching the Pub Med,Embase,The Cochrane Library,and Web of Science databases,as well as the Wangfang Data,CNKI,VIP,and CBM databases,we selected clinical randomized controlled trials(RCTs)from the time of database establishment to January 2023.Two evaluators independently conducted literature selection and data extraction,and assessed quality based on inclusion and exclusion criteria.Finally,Revman 5.4 software was used to conduct a meta-analysis of the included literature.Results:Twelve studies involving 1811 patients were included in the meta-analysis.The results indicated that,in terms of improving the International Prostate Symptom Score(IPSS)(WMD=-3.75,95% CI [-4.09,-3.41],P<0.00001),prostate volume(WMD=-4.71,95% CI [-5.38,-4.03],P<0.00001),maximum urinary flow rate(WMD=2.31,95% CI[1.92,2.69],P<0.00001),and clinical effectiveness(RR=1.19,95% CI [1.08,1.31],P=0.0003),the combination therapy group was superior to the single drug therapy group.However,there was no significant difference between the two groups in terms of improving residual urine volume(WMD=-2.41,95% CI [-16.28,11.57],P=0.74)and safety(RR=1.75,95% CI [0.53,5.77],P=0.36).Conclusion:Compared with monotherapy of Tamsulosin,Tamsulosin combined with Finasteride can significantly improve symptoms in patients with benign prostatic hyperplasia,but further research is needed from the perspective of residual urine volume improvement and safety.